FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1527263895> ?p ?o ?g. }

• W1527263895 abstract "Vintafolide (also known as EC145 or MK-8109), is a small molecule drug conjugate for the treatment of cancers expressing high affinity folate receptor (FR). Vintafolide consists of the anti-mitotic vinca alkaloid desacetylvinblastine monohydrazide (DAVLBH) chemically linked to folic acid. Binding of vintafolide to FR located on the cell surface delivers the chemotherapy payload directly to the tumor cell. Clinical investigations of vintafolide are underway in ovarian and lung cancer, indications with a high prevalence of FR expression. Triple negative breast cancer (TNBC) may represent an additional indication for vintafolide due to the prevalence of FR expression (∼30%), sensitivity to vinca alkaloids, and unmet medical need. Vintafolide and/or DAVLBH were evaluated in preclinical models of TNBC as monotherapies and in combination with taxanes (paclitaxel or docetaxel). Taxanes represent a commonly used standard of care therapy for TNBC. A panel of TNBC cell lines was generally sensitive to DAVLBH, with IC50s ranging from 4-67 nM. In the majority of cell lines tested, DAVLBH in combination with paclitaxel provided combination benefit and induced more cell death than either single agent. Vintafolide and DAVLBH were further evaluated in vivo in the FR-high MDA-MB-231 and FR-low CAL51 TNBC xenograft models. Vintafolide was dosed at its MTD of 9.6 mg/kg three times per week (TIW), and at 1.5 mg/kg TIW. DAVLBH was dosed at its MTD of 0.77 mg/kg TIW. Mice were dosed for 3 weeks followed by a 6 week follow-up. Both vintafolide doses resulted in marked MDA-MB-231 tumor regressions of 56-78% at the end of therapy (Day 21) and 75% cures (6 of 8 mice) over the 6 week follow-up period. In the CAL51 model, vintafolide produced 8% and 76% tumor growth inhibition (TGI), respectively, at the 1.5 and 9.6 mg/kg doses, and no cures. DAVLBH was less efficacious compared to vintafolide, giving 96% TGI in the MDA-MB-231 model and 46% TGI in the CAL51 model. In mechanism of action studies in the MDA-MB-231 xenograft model, a dose of vintafolide that gave tumor regressions/cures was associated with increased phospho-histone H3 staining, indicative of a mitotic block of tumor cells, and consistent with the mechanism of action of vinca alkaloids. In combination therapy experiments in vivo, docetaxel (20 mg/kg weekly) monotherapy achieved near tumor stasis (98% TGI) of MDA-MB-231 tumors over 3 weeks of therapy, but all tumors re-grew upon cessation of treatment. Since vintafolide monotherapy at 1.5 mg/kg TIW gave significant regressions and cures, a combination benefit with docetaxel could not be determined. However, DAVLBH and docetaxel combination therapy delayed tumor re-growth over single agents upon follow-up, suggesting benefit of a vinca alkaloid / taxane combination. Taken together, these preclinical data support further investigation of vintafolide monotherapy and in combination with taxane therapy in TNBC. Citation Format: Brian B. Haines, Jennifer O9Neil, Marlene C. Hinton, Christopher Ware, Tammie C. Yeh, Tianxiao Sun, Kristen L. Picard, Theresa Zhang, Emmett V. Schmidt, Isabelle Dussault. Preclinical activity of Vintafolide/MK-8109 monotherapy and in combination with standard of care therapy in triple-negative breast cancer models. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1677. doi:10.1158/1538-7445.AM2014-1677" @default.
• W1527263895 created "2016-06-24" @default.
• W1527263895 creator A5000351299 @default.
• W1527263895 creator A5015265146 @default.
• W1527263895 creator A5042503296 @default.
• W1527263895 creator A5051995874 @default.
• W1527263895 creator A5065265065 @default.
• W1527263895 creator A5072086094 @default.
• W1527263895 creator A5073783446 @default.
• W1527263895 creator A5074516218 @default.
• W1527263895 creator A5088886695 @default.
• W1527263895 creator A5091497261 @default.
• W1527263895 date "2014-09-30" @default.
• W1527263895 modified "2023-09-26" @default.
• W1527263895 title "Abstract 1677: Preclinical activity of Vintafolide/MK-8109 monotherapy and in combination with standard of care therapy in triple-negative breast cancer models" @default.
• W1527263895 doi "https://doi.org/10.1158/1538-7445.am2014-1677" @default.
• W1527263895 hasPublicationYear "2014" @default.
• W1527263895 type Work @default.
• W1527263895 sameAs 1527263895 @default.
• W1527263895 citedByCount "0" @default.
• W1527263895 crossrefType "proceedings-article" @default.
• W1527263895 hasAuthorship W1527263895A5000351299 @default.
• W1527263895 hasAuthorship W1527263895A5015265146 @default.
• W1527263895 hasAuthorship W1527263895A5042503296 @default.
• W1527263895 hasAuthorship W1527263895A5051995874 @default.
• W1527263895 hasAuthorship W1527263895A5065265065 @default.
• W1527263895 hasAuthorship W1527263895A5072086094 @default.
• W1527263895 hasAuthorship W1527263895A5073783446 @default.
• W1527263895 hasAuthorship W1527263895A5074516218 @default.
• W1527263895 hasAuthorship W1527263895A5088886695 @default.
• W1527263895 hasAuthorship W1527263895A5091497261 @default.
• W1527263895 hasConcept C121608353 @default.
• W1527263895 hasConcept C126322002 @default.
• W1527263895 hasConcept C143998085 @default.
• W1527263895 hasConcept C150903083 @default.
• W1527263895 hasConcept C207001950 @default.
• W1527263895 hasConcept C2776553716 @default.
• W1527263895 hasConcept C2776694085 @default.
• W1527263895 hasConcept C2776755627 @default.
• W1527263895 hasConcept C2776999253 @default.
• W1527263895 hasConcept C2777096885 @default.
• W1527263895 hasConcept C2777292972 @default.
• W1527263895 hasConcept C2778239845 @default.
• W1527263895 hasConcept C2779429289 @default.
• W1527263895 hasConcept C2780110267 @default.
• W1527263895 hasConcept C2780306303 @default.
• W1527263895 hasConcept C2780350996 @default.
• W1527263895 hasConcept C2781190966 @default.
• W1527263895 hasConcept C502942594 @default.
• W1527263895 hasConcept C530470458 @default.
• W1527263895 hasConcept C71924100 @default.
• W1527263895 hasConcept C86803240 @default.
• W1527263895 hasConcept C96232424 @default.
• W1527263895 hasConcept C98274493 @default.
• W1527263895 hasConceptScore W1527263895C121608353 @default.
• W1527263895 hasConceptScore W1527263895C126322002 @default.
• W1527263895 hasConceptScore W1527263895C143998085 @default.
• W1527263895 hasConceptScore W1527263895C150903083 @default.
• W1527263895 hasConceptScore W1527263895C207001950 @default.
• W1527263895 hasConceptScore W1527263895C2776553716 @default.
• W1527263895 hasConceptScore W1527263895C2776694085 @default.
• W1527263895 hasConceptScore W1527263895C2776755627 @default.
• W1527263895 hasConceptScore W1527263895C2776999253 @default.
• W1527263895 hasConceptScore W1527263895C2777096885 @default.
• W1527263895 hasConceptScore W1527263895C2777292972 @default.
• W1527263895 hasConceptScore W1527263895C2778239845 @default.
• W1527263895 hasConceptScore W1527263895C2779429289 @default.
• W1527263895 hasConceptScore W1527263895C2780110267 @default.
• W1527263895 hasConceptScore W1527263895C2780306303 @default.
• W1527263895 hasConceptScore W1527263895C2780350996 @default.
• W1527263895 hasConceptScore W1527263895C2781190966 @default.
• W1527263895 hasConceptScore W1527263895C502942594 @default.
• W1527263895 hasConceptScore W1527263895C530470458 @default.
• W1527263895 hasConceptScore W1527263895C71924100 @default.
• W1527263895 hasConceptScore W1527263895C86803240 @default.
• W1527263895 hasConceptScore W1527263895C96232424 @default.
• W1527263895 hasConceptScore W1527263895C98274493 @default.
• W1527263895 hasLocation W15272638951 @default.
• W1527263895 hasOpenAccess W1527263895 @default.
• W1527263895 hasPrimaryLocation W15272638951 @default.
• W1527263895 isParatext "false" @default.
• W1527263895 isRetracted "false" @default.
• W1527263895 magId "1527263895" @default.
• W1527263895 workType "article" @default.